GlassScriptPhysician profile
Khashayar Kash Vahdat
NPI 1528323953
$3,511.15
in general payments reported to CMS, 2019-2025
30 companies · $681 in 2025
The $681 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $171 · 2021: $276 · 2022: $568 · 2023: $548 · 2024: $250 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $504.26 | 2023-2025 | Ffrct |
| Novartis Pharmaceuticals Corporation | $425.14 | 2019-2024 | |
| Boston Scientific Corporation | $222.77 | 2019-2025 | General - Vascular Access, Versacross Access Solution |
| Janssen Pharmaceuticals, INC | $218.41 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $210.54 | 2019-2023 | Eliquis |
| Abiomed | $198.05 | 2023-2025 | Impella |
| Penumbra, INC. | $168.49 | 2025 | Indigo System |
| Abbott Laboratories | $165.87 | 2019-2025 | Xience Sierra, Cardiomems, Diamondback Peripheral |
| W. L. Gore & Associates, INC. | $147.31 | 2023-2024 | Gore Viabahn Vbx Balloon Expandable Endo, Excluder Conformable Aaa Endoprosthesis With Active Control |
| Inari Medical, INC. | $132.87 | 2022 | |
| Edwards Lifesciences Corporation | $123.31 | 2019 | |
| Amgen INC. | $119.07 | 2019-2022 | |
| Medtronic Vascular, INC. | $107.12 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $95.15 | 2021-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.23 | 2020-2025 | Lifevest |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $73.03 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Irhythm Technologies, INC. | $71.38 | 2019-2023 | Zio Xt Patch |
| Impulse Dynamics (USA) INC. | $56.69 | 2023 | Optimizer |
| Pfizer INC. | $53.64 | 2019-2022 | |
| Medtronic, INC. | $52.31 | 2023-2024 | Linq II |
| Alnylam Pharmaceuticals INC. | $49.79 | 2019 | |
| Biotronik INC. | $45.91 | 2019 | |
| Amarin Pharma, INC. | $43.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $38.02 | 2019-2022 | |
| Cardiovascular Systems INC. | $32.97 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.63 | 2021 | |
| Gilead Sciences, INC. | $16.89 | 2019 | |
| Altathera Pharmaceuticals LLC | $15.83 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.26 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khashayar Vahdat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.